Defibrillators

School officials said the cost for all 20 AEDs and replacement parts is about $35,000.

Burrall said the district’s Office of Technology and the Board of Education will fund the cost.

Copyright 2007 by wtov9.com.

All rights reserved.

This material may not be published, broadcast, rewritten or redistributed.

Email This Story Print This Story Most Popular Stories Local Stud...

Drug coatings prevent an artery from reclogging by keeping tissue from growing through the mesh, but use of the drug-coated devices has dropped off recently on concerns they raise the risk of blood clots.

Boston Scientific's Taxus stent was dealt a blow when a study delivered at the American College of Cardiology showed a stent it licenses from Abbott Laboratories outperformed the Taxus.

Stents as a whole received more bad press with another study finding that the devices did not reduce deaths or heart attacks compared with medication.

The market for implantable heart Sales of the pacemaker-like devices that shock the heart back to a normal rhythm have declined significantly since Guidant Corp., which Boston Scientific later bought, began recalling thousands of the devices in the summer of 2005 because of malfunctions.

EXPECTATIONS: Analysts surveyed by Thomson Financial estimate earnings per share of 10 cents on revenue of $2.08 billion.

ANALYST TAKE: Goldman Sachs analysts Lawrence Keusch and Charles Chon believe Taxus sales will be thin this quarter given results from main competitor Johnson & Johnson Inc.

earlier in the week.

The analysts estimate that use of drug-coated stents have fallen to 65 percent of the ti...

"Our nation's medical research and innovation give hope to patients across the world, and we can give them even better care if we have a mechanism to evaluate which medical treatments and technologies are the safest and most effective," Ignagni said.

Key elements of the new plan include: - Establishing a new national entity to evaluate and compare the safety, efficacy and cost effectiveness of new and existing health care treatments and technologies, including prescription drugs and medical devices.

- Reforming the Food and Drug Administration (FDA) to improve its ability to assess the long-term safety and effectiveness of newly approved drugs and devices.

- Setting a national research agenda that addresses known gaps in evidence and makes communication regarding ongoing research studies a national priority.

- Accelerating efforts to give patients and their physicians the information they need to make value-b...